How a Brain Peptide's Antagonists May Fight Both Inflammation and Cancer Through p53

GHRH (Growth Hormone-Releasing Hormone) antagonists exert protective effects against inflammation and cancer through p53-mediated pathways. P53 — a tumor suppressor protein frequently mutated in cancers — functions not only to regulate cell cycle, senescence, and apoptosis, but also to suppress inflammation across multiple human tissues. GHRH antagonistic analogs have been developed with clinical applications spanning benign prostatic hyperplasia, breast, prostate and lung cancers, diabetes, and neurodegenerative diseases, with their beneficial effects mediated at least partly through p53 activation.

Narrative review examining the intersection of p53 biology, GHRH peptide signaling, inflammation, and cancer. The manuscript synthesizes published research on p53's anti-inflammatory role and the mechanisms by which GHRH antagonists exert protective effects through p53-dependent pathways.

This review connects two major areas of biomedical research — GHRH peptide biology and p53 tumor suppressor pathways — in the context of inflammation and cancer. Since chronic inflammation is a well-established driver of cancer development, understanding how GHRH peptide antagonists activate p53-mediated anti-inflammatory and anticancer effects could lead to new therapeutic strategies that target both inflammation and tumor growth simultaneously.

The link between chronic inflammation and cancer is well-established — inflammatory conditions like IBD increase colorectal cancer risk, and chronic hepatitis increases liver cancer risk. Finding that GHRH peptide antagonists can simultaneously suppress inflammation and activate anticancer p53 pathways positions them as potential dual-action therapeutics. This is particularly significant because p53 is the most commonly mutated gene in cancer, and restoring its function has been a major goal of cancer research.

As a narrative review, no new experimental data is presented. The abstract discusses broad principles without quantifying the clinical efficacy of specific GHRH antagonists. The complex interplay between p53, GHRH, inflammation, and cancer involves many variables that make therapeutic predictions challenging.